{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-042354","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.059162+00:00","generated_at":"2026-05-15T06:33:00.527822+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CVRx reports preliminary Q1 2026 revenue $14.7-14.8M, +20% YoY; gross margin 87%","bullets":["Revenue expected $14.7-14.8M vs $12.3M in Q1 2025, ~20% growth.","Gross margin ~87% (84% in Q1 2025); operating expenses ~$25M vs $23.7M.","Cash and equivalents ~$72.3M at Mar 31, 2026; active implanting centers 257 (+5 vs Dec 2025).","Medicare Advantage 30-day approval rate rose to 50% in Jan-Feb 2026 vs 44% in 2025 and 31% in 2024.","First site activated in BENEFIT-HF trial on Mar 31; enrollment expected Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-042354","json":"https://secwatch.observer/filing/0001104659-26-042354.json","markdown":"https://secwatch.observer/filing/0001104659-26-042354.md","text":"https://secwatch.observer/filing/0001104659-26-042354.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926042354/0001104659-26-042354-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926042354/tm2611335d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:33:00.527822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"edf714f7bb4b7521047869b5091783325d6d3b24","claim":"CVRx, Inc. reported first quarter ended March 31, 2026 results: revenue $14.7 million to $14.8 million.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 CVRx Reports Preliminary First Quarter 2026 Financial Results · Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 · Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926042354/0001104659-26-042354-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$14.7 million to $14.8 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}